Childhood acute lymphoblastic leukaemia--current status and future perspectives.
about
Colony-stimulating factors for prevention of myelosuppressive therapy-induced febrile neutropenia in children with acute lymphoblastic leukaemiaColony stimulating factors for prevention of chemotherapy induced febrile neutropenia in children with acute lymphoblastic leukaemiaCrystal structure and allosteric regulation of the cytoplasmic Escherichia coli L-asparaginase IGenes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2Expression of the outcome predictor in acute leukemia 1 (OPAL1) gene is not an independent prognostic factor in patients treated according to COALL or St Jude protocolsEvaluation of dendritic cells loaded with apoptotic cancer cells or expressing tumour mRNA as potential cancer vaccines against leukemiaThe In Situ Tryptophan Analogue Probes the Conformational Dynamics in Asparaginase IsozymesHealth-related quality of life assessment in Indonesian childhood acute lymphoblastic leukemiaDevelopmentally regulated promoter-switch transcriptionally controls Runx1 function during embryonic hematopoiesisFlow-cytometric monitoring of disease-associated expression of 9-O-acetylated sialoglycoproteins in combination with known CD antigens, as an index for MRD in children with acute lymphoblastic leukaemia: a two-year longitudinal follow-up studyClinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia.Metabolomic high-content nuclear magnetic resonance-based drug screening of a kinase inhibitor libraryFolylpolyglutamate synthetase gene transcription is regulated by a multiprotein complex that binds the TEL-AML1 fusion in acute lymphoblastic leukemia.A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALLClinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements.Individualization of thiopurine therapy: thiopurine S-methyltransferase and beyond.Promoter polymorphisms in the β-2 adrenergic receptor are associated with drug-induced gene expression changes and response in acute lymphoblastic leukemia.The clinical relevance of detection of minimal residual disease in childhood acute lymphoblastic leukaemiaDetermination of minimal residual disease in leukaemia patients.Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia.Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: a Children's Oncology Group study.Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells.Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01.A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome.Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201.Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy.Role of cytokines in the treatment of acute leukemias: a review.Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia.Effect of Aplidin in acute lymphoblastic leukaemia cells.The evolution of freestanding children's hospitals in Canada.Butein inhibits cell proliferation and induces cell cycle arrest in acute lymphoblastic leukemia via FOXO3a/p27kip1 pathwayStatus of minimal residual disease testing in childhood haematological malignanciesMinimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the children's oncology groupRole of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia.Comparison of outcomes after HLA-matched sibling and unrelated donor transplantation for children with high-risk acute lymphoblastic leukemia.Diagnostic microarrays in hematologic oncology: applications of high- and low-density arrays.Relapse of acute lymphoblastic leukemia in children in the context of microarray analyses.L-Asparaginase as potent anti-leukemic agent and its significance of having reduced glutaminase side activity for better treatment of acute lymphoblastic leukaemia.Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.Asparaginase in the treatment of non-ALL hematologic malignancies.
P2860
Q24246566-05810D0B-70DB-491D-9496-FE0854798CD1Q24250081-976DCDC0-6D87-49EB-816C-3907B0F41700Q24681679-EB5537C0-11FD-4ED5-B16C-B051EE2301C1Q24685514-8012F58C-2758-4E35-B0D8-B99786BE6024Q24685883-EB9EF699-B7A0-4B30-BA92-8EDDBB829D90Q24800882-3D5E4A73-E6D7-486D-8E41-07132596D5C8Q30387403-B88381CD-D6E3-423C-9D73-6D746CD50DF5Q30851697-6F6C7501-5FD1-4D97-BCC0-C731AF3E0871Q33290634-08F9C334-4667-4985-8754-5012DA106F8BQ33317811-ABE431BB-205C-47BE-9B02-9F2EBF087428Q33931882-53318B07-60FF-45DC-9D32-2042BF486005Q34081089-786C1CB0-C89A-4682-8B29-E5BE4813338CQ34161064-B065E8D7-0BDE-4166-9E26-A04D08AB5887Q34217173-D03E34C0-C61C-482B-A73C-7A85D896E771Q34532636-4D17F838-A2F2-4058-9578-B1310976B584Q34996171-F91F70B9-2D98-48BC-AE07-9ED6E6C653DAQ35018371-734EC486-64C3-4163-999C-759DA20D8FE0Q35094049-552EFC8B-E799-49E0-AB0E-CB3F6EBFA942Q35145184-B39C4736-B141-4040-AAC7-55C5667937F3Q35772582-87F0BDEE-39DD-4AD4-936D-6145E361F03BQ35797316-66C16D22-D9B9-4718-A5D2-E3A70F14AF22Q35847820-E9B275B3-9129-4D71-A4D3-842D262F7955Q35849716-D4208F56-7FDA-4B20-8B3B-43C4639C5AFFQ35849791-A5A6FBC9-3C8C-4549-9570-12684ABF2478Q35925012-277113B2-1F8D-4064-85F4-E3353CAA03EDQ36402208-29E5F5D1-51B4-41F4-A8C5-24CEAB399B89Q36405044-71E2B51F-C6F8-47C9-B81A-34DE3B503961Q36425440-8928EC12-D92D-4BBB-938C-471605725BEBQ36648269-636EA71B-47FF-4ED3-8A9E-2D6945340201Q36860523-AA96D059-A127-4478-9FAD-BB6EF5FB2E5BQ37109845-F4602B98-3BD5-44F8-9E60-D5B486FAFBD3Q37246360-8C98CA62-F0FE-4404-AF98-224582FA0CBAQ37280744-66B2ED3B-164E-42BE-B26E-66433B9E8BF5Q37389544-30913B98-4597-44F7-AC56-09536B6FA47AQ37472615-8CC94524-C22C-4641-B86B-1E98EE80F26EQ37523893-38F2F99A-4F98-4395-BD6A-29A23599B36FQ37829956-0CEBA457-DA06-4D42-BDEE-F28E2E9D6263Q38017602-8E72CE5F-4022-4277-B1FE-20588BE589B7Q38113738-7CD9BD42-8D1C-40BD-8F73-F56E6EDC9AECQ38187018-2594A8BC-A7C2-4220-8763-1B2968CB2174
P2860
Childhood acute lymphoblastic leukaemia--current status and future perspectives.
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Childhood acute lymphoblastic leukaemia--current status and future perspectives.
@ast
Childhood acute lymphoblastic leukaemia--current status and future perspectives.
@en
Childhood acute lymphoblastic leukaemia--current status and future perspectives.
@nl
type
label
Childhood acute lymphoblastic leukaemia--current status and future perspectives.
@ast
Childhood acute lymphoblastic leukaemia--current status and future perspectives.
@en
Childhood acute lymphoblastic leukaemia--current status and future perspectives.
@nl
prefLabel
Childhood acute lymphoblastic leukaemia--current status and future perspectives.
@ast
Childhood acute lymphoblastic leukaemia--current status and future perspectives.
@en
Childhood acute lymphoblastic leukaemia--current status and future perspectives.
@nl
P2093
P1433
P1476
Childhood acute lymphoblastic leukaemia--current status and future perspectives.
@en
P2093
P304
P356
10.1016/S1470-2045(01)00516-2
P577
2001-10-01T00:00:00Z